Literature DB >> 17956520

Recent trends in the treatment of testosterone deficiency syndrome.

Bum Sik Hong1, Tai Young Ahn.   

Abstract

Testosterone deficiency syndrome (TDS) is defined as a clinical and biochemical syndrome associated with advancing age and is characterized by typical symptoms and deficiency in serum testosterone levels. TDS is a result of the interaction of hypothalamo-pituitary and testicular factors. Now, treatment of TDS with testosterone is still controversial due to a lack of large, controlled clinical trials on efficacy. The risks of treatment with testosterone appear to be minimal, although long-term studies on the safety of testosterone therapy are lacking. The aim of the therapy is to establish a physiological concentration of serum testosterone in order to correct the androgen deficiency, relieve its symptoms and prevent long-term sequelae. All of the available products, despite their varying pharmacodynamic and pharmacokinetic profiles, are able to reach this goal. Newer testosterone patches seem not to cause severe skin irritation. Testosterone gels minimize the skin irritation while providing flexibility in dosing and a low discontinuation rate. Oral testosterone undecanoate (TU) is free of liver toxicity. Recent formulation of oral TU markedly increased shelf-live, a major drawback in the older preparation. Producing swings in testosterone levels rising rapidly to the supraphysiological range is not the case with the new injectable long-acting preparation of TU. To be able to rapidly react and stop treatment in cases where side-effects and contraindications are detected, the short-acting transdermal and oral delivery modes have certain advantages. However, there is no evidence that the use of an injectable long-acting TU in men with TDS has limitations in clinical application for this reason. The use of dehydroepiandrosterone is still controversial because of a lack of well designed long-term trials, although some recent studies suggest positive effects on various body systems. Only a few studies have been carried out to investigate the effect of hCG (human chorionic gonadotropin) in TDS with some positive results on various body systems.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956520     DOI: 10.1111/j.1442-2042.2007.01882.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

1.  Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride.

Authors:  M Y Roth; R E Dudley; L Hull; A Leung; P Christenson; C Wang; R Swerdloff; J K Amory
Journal:  Int J Androl       Date:  2010-10-24

2.  Evaluation of Resettin® on serum hormone levels in sedentary males.

Authors:  Mark L Anderson
Journal:  J Int Soc Sports Nutr       Date:  2014-08-23       Impact factor: 5.150

3.  Development of a men's Preference for Testosterone Replacement Therapy (P-TRT) instrument.

Authors:  Sheryl L Szeinbach; Enrique Seoane-Vazquez; Kent H Summers
Journal:  Patient Prefer Adherence       Date:  2012-08-31       Impact factor: 2.711

4.  An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males.

Authors:  Fru Angwafor; Mark L Anderson
Journal:  J Int Soc Sports Nutr       Date:  2008-08-12       Impact factor: 5.150

Review 5.  Transdermal testosterone replacement therapy in men.

Authors:  M Iftekhar Ullah; Daniel M Riche; Christian A Koch
Journal:  Drug Des Devel Ther       Date:  2014-01-09       Impact factor: 4.162

Review 6.  Androgen deficiency and metabolic syndrome in men.

Authors:  Ashley G Winter; Fujun Zhao; Richard K Lee
Journal:  Transl Androl Urol       Date:  2014-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.